What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye”In the company’s words, NCT06470373 on ClinicalTrials.gov
- Main trialPhase 3
- “This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.”In the company’s words, NCT06470373 on ClinicalTrials.gov
- Copy of
- Eylea (Regeneron Pharmaceuticals)Tested side by side with the original in NCT06470373
Other drugs for Neovascular Age-related Macular Degeneration (nAMD)
- Surabgene LomparvovecAbbVie · Phase 3
- 4D-150 IVT4D Molecular Therapeutics · Phase 3
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- ElamipretideStealth BioTherapeutics Inc. · Phase 3
- ONS-5010Outlook Therapeutics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Sep 2026 | A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026